Hepatitis

13 April 2018, Paris, France: Two nationwide programmes in Georgia and Iceland, which were designed to eliminate hepatitis C virus (HCV) at the population level, have reported encouraging results, suggesting that these countries could be on target to achieve their elimination goals. Although both programmes have adopted slightly different approaches, both have reported high levels

Hepatitis C is not a visible virus. It disproportionately affects disadvantaged and marginalised communities, with almost half of people who attend hospital for hepatitis C coming from the poorest fifth of society. People living with hepatitis C often experience few obvious symptoms, and 40-50% of the estimated 160,000 with hepatitis C in England are unaware

Hepatitis C infection is a global phenomenon that affects millions worldwide, with an estimated 30,500 new cases in the United States alone each year. Expanding treatment, however, could go a long way toward preventing transmission of the virus among high-risk individuals who inject drugs, according to new Yale-led research. For the study, infectious disease experts

Diabetes Canada adapting made-in-BC Treatment as Prevention (TasP¨) strategy to diabetes, making 6 million Canadians aware of their status VANCOUVER, Oct. 20, 2017 /CNW/ – Diabetes Canada is adopting the BC Centre for Excellence in HIV/AIDS Treatment as Prevention¨ (TasP¨) approach to tackle the epidemic of diabetes and prediabetes currently affecting over 11 million Canadians.

People who inject drugs have historically represented a population at high risk for hepatitis C virus. However, these patients are often wary of authority figures or entities that might draw attention to or monitor their behavior. This caution may negatively affect their incentive to pursue treatment. The significant side effects of interferon-based therapies – previously